Teragen Bio Registers Patent for AI Platform Neoantigen Vaccine Design Program

Hwang Tae-soon, CEO of Theragen Bio

[Asia Economy Reporter Lee Gwanju] Teragen Bio, a global genome analysis service and AI-based new drug development company, announced on the 6th that it has completed patent registration for its AI-based cancer vaccine development platform 'DEEPOMICS® NEO' regarding the 'device for immunogenicity prediction of synthetic long peptides, immunogenicity prediction method, and computer program.'

The newly registered patent relates to a method for effectively measuring the immunogenicity of synthetic long peptides (SLP) included in neoantigen vaccines and designing vaccines that maximize the immunogenicity of neoantigen candidates selected through genome analysis and experiments.

'DEEPOMICS® NEO' is a program that quantifies and calculates the immunogenicity of SLPs presented by the injection to be administered to patients by evaluating ▲neoantigen HLA binding affinity ▲T cell recognition ▲cleavage prediction information ▲peptide sequence information injected into the patient's target cells, and identifies the optimal mutation position within the SLP sequence.

Baek Soonmyung, Director (CTO) of Teragen Bio, said, "Cancer vaccines designed using this patent have shown superior immune response induction and therapeutic effects in preclinical models compared to competitors, and it is an advanced technology applicable to all vaccine designs." He added, "Through continuous research and development, we will achieve the realization of personalized medicine and the goal of developing treatments for intractable cancers."

Teragen Bio is currently researching and developing therapeutic neoantigen cancer vaccines that selectively stimulate T cells recognizing tumor mutations to activate immune cells. The neoantigen cancer vaccine field is gaining attention in cancer drug development because it applies the concept of personalized medicine by selecting neoantigens based on the unique tumor mutation information of each individual.

Teragen Bio has so far obtained 2 patents for 'DEEPOMICS® MARKER' and 4 patents for 'DEEPOMICS® NEO,' completing a total of 6 patent registrations related to cancer vaccine platforms. Moving forward, the company plans to continue research on patient-specific customized therapeutic targets and new drug development to create the genome big data platform 'DEEPOMICS®' and genome-based innovative solutions.